Harbinger Health

The post Getting potential cancer patients out of diagnostic limbo appeared first on Harbinger Health.

Jack Meehan of Operon Research sits down with Ajit Singh, CEO of Harbinger Health, to unpack the state of liquid biopsy and multi-cancer early detection. They discuss why Harbinger is targeting the "concerned" population rather than asymptomatic screening

ASCO Annual Meeting 2026 Radiographic findings suspicious for malignancy can trigger prolonged, inconclusive diagnostic workups, and the performance of cfDNA methylation-based MCED assays in this diagnostic setting remains less well characterized than in

Harbinger Health, a biotechnology company pioneering cancer resolution, today announced the presentation of clinical data on Harbinger

Harbinger Health Presents Clinical Data at ASCO Supporting RESOLVE as a New Blood-Based Category for Evaluation of Suspected Cancer Presentation highlights test performance in individuals presenting with signs, symptoms, or findings suggestive of cancer,

Digestive Disease Week (DDW) 2026 This study describes the use of a blood-based prioritization test that stratifies molecular-test-positive patients by colorectal cancer risk to help identify those who may benefit from earlier colonoscopy. This strategy c

The post Three Questions with Ajit Singh, Flagship CEO-Partner appeared first on Harbinger Health.

American Association for Cancer Research (AACR) Annual Meeting 2026 This study demonstrated use of a cell-free DNA methylation assay to predict lung tumor size and metastatic state, key factors influencing tumor DNA levels in blood. Results suggest that l

American Association for Cancer Research (AACR) Annual Meeting 2026 ProbeCDN is a deep-learning framework that detects cancer by analyzing methylation patterns at the level of individual DNA reads, overcoming limitations of traditional methods that dilute